NASDAQ:VCNXVaccinex Stock Price, Forecast & News

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VCNX shares have decreased by 11.3% and is now trading at $3.70. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaccinex.

Vaccinex is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Vaccinex.

Vaccinex Inc (NASDAQ:VCNX) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.75) by $0.30. Vaccinex had a negative return on equity of 2,277.96% and a negative net margin of 4,740.03%. View Vaccinex's earnings history.

1 Wall Street analysts have issued 1 year price targets for Vaccinex's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's stock price to reach $22.00 in the next year. This suggests a possible upside of 494.6% from the stock's current price. View analysts' price targets for Vaccinex.

Media headlines about VCNX stock have been trending negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vaccinex earned a daily sentiment score of -2.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutVaccinex.

Vaccinex saw a increase in short interest in May. As of May 15th, there was short interest totaling 190,000 shares, an increase of 13.2% from the April 30th total of 167,900 shares. Based on an average daily trading volume, of 38,000 shares, the short-interest ratio is currently 5.0 days. Currently, 6.4% of the company's stock are sold short. View Vaccinex's Current Options Chain.

Some companies that are related to Vaccinex include REDHILL BIOPHAR/S (RDHL), Spero Therapeutics (SPRO), MediciNova (MNOV), Fortress Biotech (FBIO), Affimed (AFMD), Northwest Biotherapeutics (NWBO), Mallinckrodt (MNK), Hookipa Pharma (HOOK), XOMA (XOMA), Marinus Pharmaceuticals (MRNS), Inflarx (IFRX), Five Prime Therapeutics (FPRX), Lexicon Pharmaceuticals (LXRX), LifeVantage (LFVN) and OptiNose (OPTN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Exelixis (EXEL), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Opko Health (OPK), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Whiting Petroleum (WLL).

(VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Vaccinex's stock is owned by a number of institutional and retail investors. Top institutional shareholders include MSD Partners L.P. (7.10%). Company insiders that own Vaccinex stock include Albert Friedberg, Catalyst Group Managem General, Maurice Zauderer and Scott E Royer. View institutional ownership trends for Vaccinex.

VCNX stock was sold by a variety of institutional investors in the last quarter, including MSD Partners L.P.. View insider buying and selling activity for Vaccinex.

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCNX stock can currently be purchased for approximately $3.70.

Vaccinex has a market capitalization of $61.59 million and generates $520,000.00 in revenue each year. The company earns $-31,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Vaccinex employs 44 workers across the globe.

The official website for Vaccinex is www.vaccinex.com.

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]